Alzheimer’s Therapeutics Market Size, Share

The global Alzheimer’s therapeutics market is projected to expand from approximately USD 4.82 billion in 2023 to over USD 8.18 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.7% from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5130

Report Highlights

• Cholinesterase inhibitors lead the market with a commanding 50% market share in 2023.
• Combination drugs are projected to register the fastest growth with 6.2% CAGR over the forecast period.
• Hospital pharmacies were the largest contributors to the market in 2023.

The National Center for Biotechnology Information reported that in 2021, around 6.2 million Americans aged 65 and older had Alzheimer’s disease. By 2060, this number is expected to double to about 13.8 million nearly. Women are more likely to get Alzheimer’s because they tend to live longer. Alzheimer’s is becoming the top cause of death among neurodegenerative diseases and can lead to physical disability, needing prompt treatment. 

Alzheimer’s disease is a type of dementia that affects memory, thinking, and behavior. It’s caused by changes in the brain that lead to the death of brain cells. These changes can make it hard for people with Alzheimer’s to remember things, communicate, and take care of themselves.

The exact cause of Alzheimer’s disease isn’t fully understood, but scientists believe it’s a combination of genetic, environmental, and lifestyle factors. As people age, their risk of developing Alzheimer’s disease increases, but it can also affect younger people.

For instance,

• In 2021, a Special Report discussed people’s and doctors’ views on identifying, diagnosing, and treating mild cognitive impairment (MCI), which can be linked to Alzheimer’s disease (AD). Currently, about 6.5 million Americans aged 65 and above have Alzheimer’s dementia. If there are no new treatments to stop, delay, or cure AD, this number could double to 13.8 million.

It’s essential to treat and manage Alzheimer’s disease because it can significantly affect a person’s quality of life and ability to function independently. There’s currently no cure for Alzheimer’s disease, but treatment options are available to help manage symptoms and slow down the progression of the disease. This can include medications to improve memory and thinking and therapies to help with communication and daily activities.

Additionally, proper management of Alzheimer’s disease can help improve the quality of life for both the person with the disease and their caregivers. This may involve creating a safe and supportive environment, providing assistance with daily tasks, and offering emotional support and resources for caregivers. Early diagnosis and intervention are crucial to helping people with Alzheimer’s disease live as independently and comfortably as possible for as long as possible.

Highlights of Prevalence of Alzheimer’s Disease

• In 2023, about 6.7 million Americans aged 65 and above have Alzheimer’s, with most of them being 75 or older.
• Around 1 in 9 people aged 65 or older (10.7%) have Alzheimer’s.
• Nearly two-thirds of those with Alzheimer’s in the US are women.
• As the elderly population in the US grows, so will the number of people with Alzheimer’s. By 2050, it may reach 12.7 million unless new treatments are found.

The Role of Hospitals in Supporting Alzheimer’s Patients

Hospitals play a crucial role in assisting individuals with Alzheimer’s disease. They are equipped with specialized teams of healthcare professionals, including doctors and nurses, who have extensive knowledge about Alzheimer’s and its treatment. In a hospital setting, patients have access to advanced diagnostic tools such as MRIs and PET scans, which allow doctors to observe changes in the brain. Early diagnosis of Alzheimer’s is vital, as it facilitates appropriate treatment and optimizes patient outcomes.

Within hospitals, patients benefit from a multidisciplinary approach involving various specialists, such as neurologists, geriatricians, and psychiatrists. These experts collaborate to provide comprehensive care tailored to the unique needs of each patient. Hospitals also offer a range of treatment options for Alzheimer’s, including medications, cognitive therapy to improve memory and thinking skills, and support services for both patients and their families.

For example, according to a 2022 report by the Alzheimer’s Association, there are 518 hospitalizations per 1,000 elderly Medicare beneficiaries diagnosed with Alzheimer’s or other dementias, compared to just 234 hospitalizations per 1,000 individuals without these conditions. Although the number of hospitalizations for Alzheimer’s patients is significant, projections indicate that this trend will remain relatively stable despite the growing prevalence of the disease.

Moreover, many hospitals are involved in research efforts to discover new treatments for Alzheimer’s. They conduct clinical trials to evaluate the efficacy of new medications and therapies, striving to enhance patient care. For those experiencing more severe forms of the disease, hospitals often have specialized units that provide intensive care and support.

In summary, hospitals are a primary resource for individuals with Alzheimer’s, offering diagnosis, treatment options, research for new therapies, and support for patients and their families. As the aging population increases the number of individuals diagnosed with Alzheimer’s, hospitals will continue to play an essential role in delivering necessary care and support.

Regulatory Hurdles and Challenges

Developing and approving new treatments for Alzheimer’s faces significant regulatory hurdles and challenges, primarily due to strict guidelines set by government agencies like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations are designed to ensure the safety and effectiveness of new drugs, but they can also slow down the development process and increase costs.

Clinical trial design for Alzheimer’s poses unique challenges. One major issue is determining the appropriate outcome measures to evaluate whether a new treatment is effective. Given the varying ways in which Alzheimer’s impacts individuals, selecting the right metrics to assess improvement is crucial.

Additionally, deciding on the participant criteria for clinical trials presents its own set of difficulties. Researchers must enroll individuals diagnosed with Alzheimer’s while ensuring that participants share similar characteristics to achieve reliable results. This can be complicated, as Alzheimer’s affects each person differently, often alongside other health conditions.

Navigating these regulatory hurdles and designing effective clinical trials requires meticulous planning and attention to detail. However, it is vital to ensure that any new treatments for Alzheimer’s are both safe and effective before they become available to the public.

Alzheimer’s Therapeutics Market Companies

• Biogen Inc.
• Eli Lilly and Company
• Eisai Co., Ltd
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc
• AbbVie Inc.

Alzheimer’s Therapeutics Market Segments

By Product Type

• Cholinesterase Inhibitors
  • Donepezil
  • Galantamine
  • Rivastigmine
• NMDA Receptor Antagonist
• Combination Drugs
• Pipeline Drugs

By End User

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce

By Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/alzheimers-therapeutics-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5130

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare